# OnCo record halozyme (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/halozyme/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "halozyme" ;
  schema:name "Halozyme Therapeutics"@en ;
  schema:alternateName "Halozyme Therapeutics, Inc."@en, "Halozyme"@en ;
  schema:description "Halozyme's recombinant hyaluronidase (ENHANZE) is what lets antibodies such as rituximab, trastuzumab and daratumumab be given as quick under-the-skin injections instead of long infusions; its own tumour-targeting version failed in pancreatic cancer."@en ;
  schema:url <https://onco.cc/companies/halozyme/>, <https://www.halozyme.com> ;
  schema:dateModified "2026-09-11"^^xsd:date ;
  schema:citation <https://www.halozyme.com>, <https://clinicaltrials.gov/search?lead=Halozyme%20Therapeutics%2C%20Inc.>, <https://www.wikidata.org/wiki/Q5643474> ;
  onco:tag "ctgov-sponsor" ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/pancreatic/> ;
  onco:drugs <https://onco.cc/drugs/rituximab/>, <https://onco.cc/drugs/trastuzumab/>, <https://onco.cc/drugs/daratumumab/> ;
  onco:terms <https://onco.cc/terms/pivotal-trial/>, <https://onco.cc/terms/clinical-trial/> .